Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection

Documenti analoghi

• Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38(+) tumors in mouse models in vivo
  di: Fumey, William, et al.
  Pubblicazione: (2017)
• Daratumumab and Nanobody-Based Heavy Chain Antibodies Inhibit the ADPR Cyclase but not the NAD(+) Hydrolase Activity of CD38-Expressing Multiple Myeloma Cells
  di: Baum, Natalie, et al.
  Pubblicazione: (2020)
• Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
  di: Bannas, Peter, et al.
  Pubblicazione: (2018)
• Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
  di: Schriewer, Levin, et al.
  Pubblicazione: (2020)
• Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs)
  di: Hambach, Julia, et al.
  Pubblicazione: (2020)